Երկիր: Ավստրալիա
Լեզու: անգլերեն
Աղբյուրը: Department of Health (Therapeutic Goods Administration)
ceftazidime pentahydrate
Alphapharm Pty Ltd
ceftazidime pentahydrate
Registered
CEFTAZIDIME MYLAN 1 CEFTAZIDIME MYLAN _contains the active ingredient Ceftazidime pentahydrate _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about CEFTAZIDIME MYLAN. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking CEFTAZIDIME MYLAN against the benefits expected for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, TALK TO YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may need to read it again. WHAT CEFTAZIDIME MYLAN IS USED FOR CEFTAZIDIME MYLAN contains ceftazidime (as pentahydrate) as the active ingredient. It belongs to a group of antibiotics called cephalosporins. It is used to treat a wide range of infections caused by bacteria. These infections may affect the chest (bronchitis or pneumonia), ears, nose, throat, bladder and urinary tract, skin and soft tissue, stomach or bones. It works by killing the bacteria that cause these. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. This medicine/It is available only with a doctor's prescription. This medicine is not addictive. BEFORE YOU ARE GIVEN IT _WHEN YOU MUST NOT BE GIVEN _ _IT _ YOU MUST NOT BE GIVEN CEFTAZIDIME MYLAN IF YOU HAVE OR HAVE HAD AN ALLERGY TO: any medicine containing ceftazidime any other cephalosporin antibiotic major allergy to penicillin If you are allergic to cephalosporin or penicillin you may have an increased chance of being allergic to CEFTAZIDIME MYLAN. Any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include; shortness of breath wheezing or difficulty breathing swelling of the face, lips, tongue or other parts of the body rash, itching or hives on the skin CEFTAZIDIME MYLAN SHOULD NOT BE MIXED WITH LIGNOCAINE Կարդացեք ամբողջական փաստաթուղթը
PRODUCT INFORMATION CEFTAZIDIME MYLAN _Ceftazidime (as pentahydrate) _ NAME OF THE MEDICINE Active ingredient : Ceftazidime (as pentahydrate) Chemical name : (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-[(1-carboxyl-1- methylethoxy)imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)methyl]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylate pentahydrate Structural formula : Molecular weight : 637.0 CAS Registry no. : 78439-06-2 DESCRIPTION Ceftazidine is a cephalosporin antibiotic for use by injection only. CEFTAZIDIME MYLAN powder for injection is a white or almost white crystalline powder of ceftazidime pentahydrate (sterile and buffered with sodium carbonate) equivalent to 1 g or 2 g ceftazidime (on dried and sodium carbonate free basis). On the addition of water for injections, CEFTAZIDIME MYLAN powder for injection dissolves with effervescence to produce a solution for injection. CEFTAZIDIME MYLAN powder for injection contains approximately 50.5 mg (2.2 mEq) of sodium per gram of ceftazidime. For laboratory tests associated with ceftazidime administration, ceftazidime pentahydrate should be used. PHARMACOLOGY PHARMACOKINETICS Absorption of ceftazidime after oral administration is negligible, therefore CEFTAZIDIME MYLAN is intended for parenteral use only. In humans, after a single intramuscular administration of 500 mg and 1 g, mean peak serum levels of 18 mg/L and 37 mg/L respectively are achieved at 1 hour, falling to 8 mg/L and 2 mg/L (500 mg) and 20 mg/L and 5 mg/L (1 g) at four hours and eight hours respectively for the two doses. Five minutes after an intravenous bolus injection of 500 mg, 1 g and 2 g, mean serum levels are respectively 46 mg/L, 87 mg/L and 170 mg/L, falling to 17 mg/L and 6 mg/L (500 mg), 32 mg/L and 10 mg/L (1 g) and 85 mg/L and 15 mg/L (2 g) at one and four hours respectively with the three doses. The serum half-life in adults with normal renal function is about 1.8 hours (1.2-2.9 hours). This may be prolonged to 20-35 hours in anuric patients. In neonates, the serum half-life of ceftazidime ca Կարդացեք ամբողջական փաստաթուղթը